TrialBlood advances2025

Zanubrutinib is well tolerated and effective in patients with CLL/SLL intolerant of ibrutinib/acalabrutinib: updated results.

Mazyar Shadman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.